BZD use and increased severity of COVID-19
Chronic use of benzodiazepines (BZD) resulted in an increase in the risk of requiring hospitalisation among COVID-19 patients, observed a recent study published in Research Square preprint server. The research team analysed 328,373 individuals, divided into two groups as individuals who did not use BZD and individuals who used BZD, from the National Health Information Database (NHID) on Covid from National Health Insurance Service (NHIS) between 2015 and 2020. The results showed that 5·5% of the BZD use group died while 10·3% required ICU or invasive ventilation support and 87·4% of Covid -19 patients who used BZD had required hospitalisation. These findings were in line with previous studies that reported increased susceptibility to superinfections associated with BZD use in influenza-infected animals and humans.